Chronic candidal osteomyelitis of mid face: A therapeutic dilemma

Rishi Bali1, Parveen Sharma1, Prachi Gupta2

  • 1Professor, Department of OMFS, DAV Dental College and MM General Hospital, Yamunanagar Haryana 135001, India ; Pt. B.D. Sharma University of Health Sciences, Haryana, India.

Insights

This case report highlights a rare instance of maxillary osteomyelitis caused by Candida albicans, a common oral fungus. Further multicenter studies are needed to establish effective treatment guidelines for this challenging fungal infection.

Area of Science:

  • Medical Mycology
  • Infectious Diseases
  • Oral and Maxillofacial Surgery

Background:

  • Rising incidence of fungal infections linked to immunosuppression, broad-spectrum antibiotics, antineoplastics, and prosthetic devices.
  • Candida albicans, a commensal of the oral cavity, is infrequently associated with maxillary osteomyelitis.
  • Diagnosis of candidal infections presents challenges due to non-specific symptoms and delayed culture positivity.

Purpose of the Study:

  • To report a rare case of candidal osteomyelitis affecting the mid-face.
  • To underscore the diagnostic difficulties and treatment uncertainties associated with this condition.
  • To advocate for further research into optimal therapeutic strategies.

Main Methods:

  • Case presentation of a patient with maxillary osteomyelitis.
  • Review of relevant literature on candidal osteomyelitis.
  • Clinical and microbiological assessment.

Main Results:

  • A case of maxillary osteomyelitis caused by Candida albicans was successfully identified and managed.
  • The study highlights the diagnostic challenges and limited existing treatment guidelines for such infections.
  • The rarity of this condition in the literature is emphasized.

Conclusions:

  • Candidal osteomyelitis of the mid-face is an uncommon but significant clinical entity.
  • The lack of established treatment protocols necessitates further multicenter, long-term investigations.
  • Developing robust guidelines is crucial for improving patient outcomes in rare fungal infections.